Dear Sir,

We read with interest the article entitled 'Decreased albuminuria by Pravastatin in hyperlipaemic diabetics', in volume 59, No. 4,1991, of Nephron [1]. Recently, we completed a study entitled, 'Effect of pentoxifylline in the management of proteinuria amongst diabetics'. The study was conducted on 20 patients showing clinical evidence of diabetic nephropathy in the form of overt proteinuria and evidence of diabetic nephropathy with or without compromised renal function. The majority of patients had maturity-onset diabetes (80%) and 20% were non-insulin dependent. Evidence of triopathy (neuropathy, retinopathy and nephropathy) was present amongst 25% of the cases. 50% had diabetes of less than 10 years’ duration where as 25% patients had diabetes of more than 15 years. Most of the patients in the hypertensive group were azotemic, with mean serum creatinine values of 2.6 ± 0.6 mg/dl, whereas, amongst the normotensive group, serum creatinine was normal. All patients had overt proteinuria of more than 1 g/24 h. Amongst the hypertensive group, proteinuria ranged between 2.25 and 900 g/day, whereas, in the normotensive group, it was between 1.05 and 5.10 g/day (fig. 1). After a follow-up of 3 consecutive months with pentoxifylline, 1,200 mg in divided doses/day, there was a significant reduction in mean proteinuria values (hypertensive group: 6.2 ± 2.4 to 3.8 ± 2.1 g/day; normotensive group: 2.9 ± 1.5 to 2.1 ± 1.6 g/day, p < 0.01) (fig. 1). The hypertensive group did not receive antihypertensive drugs, and those who developed hypertensive crisis were dropped from the study. There was a significant improvement in the mean glomerular filtration rate (hypertensive group: 40.0 ± 11.9 to 48.1 ± 12.9 ml/min; normotensive group: 74.0 ± 35.1 to 81.9 ± 25.0 ml/min; fig. 2) and also a reduction in blood urea and serum creatinine. The responses were more obvious amongst normotensives than amongst hypertensives.

Before pentoxifylline

Hypertensive

<table>
<thead>
<tr>
<th>K. Tripathi</th>
<th>J. Jai Prakash</th>
<th>D. Deoraj Appaiha</th>
<th>P.K. Srivastava</th>
</tr>
</thead>
</table>

Department of Medicine and Nephrology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India

K. Tripathi, Reader, Dept. of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221005 (India)
Pentoxifylline is being used to improve rheology and microcirculation in peripheral vascular diseases [2]. Most of the beneficial results have been demonstrated in those patients who had an associated cerebrovascular accident [3]. Recently, two such works have been published from this country [4, 5], though none of the authors, including this one, has used microalbuminuria. This technique is not readily available in developing countries whereas estimation of gross proteinuria is very economical and can be used to monitor the clinical response amongst patients of diabetic nephropathy. Solerte and Ferrari [6] have also demonstrated that normalization of blood rheology leads to a marked reduction in proteinuria and albumin excretion, and this has also been our observation. The drug seems to be promising as, contrary to converting enzyme inhibitors, it does not produce a reduction in glomerular filtration rate and hyperkalemia amongst diabetics.

References


